Oncology Learning Network

Oncology Learning Network
Long-Lasting Remission With Dual Targeting CAR-T Therapy for R/R DLBCL

Patients with relapsed/refractory DLBCL given AUTO3 in combination with pembrolizumab experienced durable complete remissions, according to data presented by Aravind Ramakrishnan, MD.

Oncology Learning Network
ViPOR Yields Complete Response in Patients with R/R B-Cell NHL

In a phase 1b/2 study of patients with relapsed/refractory B-cell non-Hodgkin's lymphoma, the ViPOR regimen led to complete responses, with no unexpected toxicities.

Oncology Learning Network
Exploring Dosing Regimens of Sabatolimab Therapy for MDS/AML

Study findings support further exploration of specific dosing regimens of sabatolimab in patients with intermediate- to very high-risk MDS or AML.

Oncology Learning Network
Better EFS With Blinatumomab vs Chemo for High-Risk First Relapse of BCP-ALL

This study suggests blinatumomab monotherapy as a new standard-of-care consolidation therapy before allogeneic hematopoietic stem cell transplant in young patients with high-risk first-relapse BCP-

Oncology Learning Network
Mosunetuzumab Safe, Effective for Elderly Patients With DLBCL

Single-agent mosunetuzumab demonstrated efficacy, remarkable safety, as a chemotherapy-free option for previously untreated elderly/unfit patients with DLBCL.

Oncology Learning Network
R-CHOP, Rituximab Maintenance Therapy Extend PFS in Patients With Newly Diagnosed FL

Rituximab maintenance therapy significantly prolonged PFS in patients with newly diagnosed FL given R-CHOP versus rituximab plus bendamustine...

Oncology Learning Network
Frailty Tied to Increased 1-Year Mortality in Patients with Newly Diagnosed DLBCL

According to data presented at the 2020 ASH Annual Meeting and Exposition, fragility in patients with DLBCL is significantly associated with 1-year mortality.

Oncology Learning Network
Polatuzumab Vedotin Plus Venetoclax, Rituximab Shows Promise in R/R DLBCL

Polatuzumab vedotin plus venetoclax with rituximab (Pola-Ven-R) shows promise in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

Oncology Learning Network
DNA Alterations Can Predict Risk for Melanoma Earlier

Melanoma can be predicted long before any suspicious moles are detected thanks to the identification of DNA mutations in individual skin cells.

Oncology Learning Network
Axi-Cel for NHL Yields Similar Responses in Real-World and Trial Setting
A study evaluating the efficacy and safety of axicabtagene ciloleucel (axi-cel) for NHL in non-trial settings showed that outcomes remained consistent with that observed in studies of the drug.
Oncology Learning Network
Subscribe to Oncology Learning Network

source list reference